BRD4 inhibition can down-regulate growth-associated transcription factors MYC and E2F, resulting in antiproliferative effects across DLBCL subtypes, which proved BRD4 to be a particularly appealing target in DLBCL [18–21]. This evidence concerns the gene BRD4 and diffuse large B-cell lymphoma.